RecruitingPhase 1Phase 2NCT07495956

cfMSC Therapy for Diabetes

Clonal Fetal Mesenchymal Stem Cell (cfMSC) Therapy for Type II Diabetes Mellitus

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment

30 participants

Start Date

Mar 16, 2026

Study Type

INTERVENTIONAL

Conditions

Type II Diabetes Mellitus

Summary

The purpose of this study is to assess the feasibility, safety and clinical efficacy of the novel clonal fetal mesenchymal stem cell (cfMSC) therapy in patients with type II diabetes mellitus.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called cfMSC therapy for diabetes for people with type ii diabetes mellitus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.